Revelation Biosciences reports FY2022 net loss $10.8M; cash $5.3M through June 2024

REVELATION BIOSCIENCES, INC.

2023-Q1 EPS reported $1.96

Cash and cash equivalents $5.3M at Dec 31, 2022 vs $1.3M year ago; $15.6M public offering completed.
Net loss for FY2022 $10.8M ($20.09 per share) vs $12.0M ($42.50 per share) in 2021.
Operating cash burn $11.2M for FY2022 vs $11.1M in prior year.
Plans to start combined Phase 1a clinical study for REVTx-300 and REVTx-100 in H2 2023.
Management believes cash sufficient to fund operations through June 2024.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

REVELATION BIOSCIENCES, INC. reported twelve months ended December 31, 2022 results: net income $10.8 million, EPS $20.09 per share.

Period: twelve months ended December 31, 2022
Net income: $10.8 million
EPS: $20.09 per share
Result: reported results

Exact text from the filing

Revelation’s net loss for the three and twelve months ended December 31, 2022 was $1.2 million and $10.8 million, or $1.77 per share and $20.09 per share, respectively

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

REVELATION BIOSCIENCES, INC. reported three months ended December 31, 2022 results: net income $1.2 million, EPS $1.77 per share.

Period: three months ended December 31, 2022
Net income: $1.2 million
EPS: $1.77 per share
Result: reported results

Exact text from the filing

Revelation’s net loss for the three and twelve months ended December 31, 2022 was $1.2 million and $10.8 million, or $1.77 per share and $20.09 per share, respectively

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

REVELATION BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0000950170-23-011612

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.